Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Targeting the p27 Kip1 E3 Ubiquitin Ligase for the Treatment of Multiple Myeloma and Other Hematological Malignancies.

Qing Chen, PhD, Weilin Xie, PhD, Deborah J. Kuhn, PhD, Peter M. Voorhees, MD, Derek Mendy, MD, Antonia Lopez-Girona, PhD, Veronique Plantevin, PhD, Weiming Xu, PhD, Laura De Parseval, PhD, Laura G. Corral, PhD, Emilia Glezer, PhD, Kyle Chan, PhD, Frank Mercurio, PhD, Robert Z. Orlowski, MD, PhD

Blood (2006) 108 (11): 372.

https://doi.org/10.1182/blood.V108.11.372.372

Published: 2006

Journal Articles

Development of Immunoproteasome-Specific Inhibitors as Novel Anti-Cancer Drugs.

Deborah J. Kuhn, PhD, Peter M. Voorhees, MD, Qing Chen, PhD, John S. Strader, Frank Bruzzese, PhD, Jeffrey P. Ciavarri, PhD, Zhigen Hu, PhD, Robert Z. Orlowski, MD, PhD

Blood (2006) 108 (11): 3458.

https://doi.org/10.1182/blood.V108.11.3458.3458

Published: 2006

Journal Articles

The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance.

Deborah J. Kuhn, PhD, Qing Chen, PhD, Peter M. Voorhees, MD, John S. Strader, Kevin D. Shenk, PhD, Congcong M. Sun, PhD, Susan D. Demo, PhD, Mark K. Bennett, PhD, Fred W. van Leeuwen, PhD, Robert Z. Orlowski, MD, PhD

Blood (2006) 108 (11): 3461.

https://doi.org/10.1182/blood.V108.11.3461.3461

Published: 2006

Journal Articles

Inhibition of Kinesin Spindle Protein Induces Apoptosis and Overcomes Drug Resistance in Models of Multiple Myeloma.

Qing Chen, PhD, Vishwan Pamarthi, Deborah J. Kuhn, PhD, Peter M. Voorhees, MD, John S. Strader, Robert Z. Orlowski, MD, PhD

Blood (2006) 108 (11): 3425.

https://doi.org/10.1182/blood.V108.11.3425.3425

Published: 2006

Journal Articles

Identification of Novel Inhibitors That Specifically Target the Immunoproteasome, and Selectively Induce Apoptosis in Multiple Myeloma and Other Immunoproteasome-Expressing Model Systems.

Robert Z. Orlowski, MD, PhD, Deborah J. Kuhn, PhD, George W. Small, PhD, Charlene Michaud, BA, Marian Orlowski, MD

Blood (2005) 106 (11): 248.

https://doi.org/10.1182/blood.V106.11.248.248

Published: 2005

Journal Articles

Inhibition of Interleukin-6 Signaling with CNTO328 Sensitizes Multiple Myeloma Cells to Bortezomib and Attenuates Proteasome Inhibitor-Mediated Induction of the Anti-Apoptotic Heat Shock Protein Response.

Peter M. Voorhees, MD, Deborah J. Kuhn, PhD, George W. Small, PhD, John S. Strader, PA, Robert Corringham, MD, Mohamed H. Zaki, MD, PhD, Jeffrey Nemeth, PhD, Robert Z. Orlowski, MD, PhD

Blood (2005) 106 (11): 1574.

https://doi.org/10.1182/blood.V106.11.1574.1574

Published: 2005

Journal Articles

Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma.

Deborah J. Kuhn, PhD, Peter M. Voorhees, MD, John S. Strader, PA, Kevin D. Shenk, PhD, Congcong M. Sun, PhD, Susan D. Demo, PhD, Mark K. Bennett, PhD, Robert Z. Orlowski, MD, PhD

Blood (2005) 106 (11): 1576.

https://doi.org/10.1182/blood.V106.11.1576.1576

Published: 2005

NARROW

Targeting the p27 Kip1 E3 Ubiquitin Ligase for the Treatment of Multiple Myeloma and Other Hematological Malignancies.

Development of Immunoproteasome-Specific Inhibitors as Novel Anti-Cancer Drugs.

The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance.

Inhibition of Kinesin Spindle Protein Induces Apoptosis and Overcomes Drug Resistance in Models of Multiple Myeloma.

Identification of Novel Inhibitors That Specifically Target the Immunoproteasome, and Selectively Induce Apoptosis in Multiple Myeloma and Other Immunoproteasome-Expressing Model Systems.

Inhibition of Interleukin-6 Signaling with CNTO328 Sensitizes Multiple Myeloma Cells to Bortezomib and Attenuates Proteasome Inhibitor-Mediated Induction of the Anti-Apoptotic Heat Shock Protein Response.

Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Targeting the p27 Kip1 E3 Ubiquitin Ligase for the Treatment of Multiple Myeloma and Other Hematological Malignancies.

Development of Immunoproteasome-Specific Inhibitors as Novel Anti-Cancer Drugs.

The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance.

Inhibition of Kinesin Spindle Protein Induces Apoptosis and Overcomes Drug Resistance in Models of Multiple Myeloma.

Identification of Novel Inhibitors That Specifically Target the Immunoproteasome, and Selectively Induce Apoptosis in Multiple Myeloma and Other Immunoproteasome-Expressing Model Systems.

Inhibition of Interleukin-6 Signaling with CNTO328 Sensitizes Multiple Myeloma Cells to Bortezomib and Attenuates Proteasome Inhibitor-Mediated Induction of the Anti-Apoptotic Heat Shock Protein Response.

Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only